关键词: font-size:medium, ">安罗替尼；化疗；晚期非小细胞肺癌；毒副作用

Abstract: Objective： To investigate the efficacy and side effects of anrotinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods： Retrospective analysis was performed on 60 patients with advanced NSCLC admitted to our hospital from May 2018 to October 2019. They were divided into two groups according to different treatment regimens， namely the control group (n=30)， which was treated with chemotherapy， and the observation group (n=30)， which was treated with anrotinib combined with chemotherapy.The short-term effect， improvement rate of quality of life and adverse reactions of the two groups were compared. Results： The short-term total effective rate of the observation group was 83.33%， higher than that of the control group (53.33%)， and the improvement rate of the quality of life of the observation group was 56.67%， higher than that of the control group (26.67%)， the difference was statistically significant (P<0.05). The classification of adverse reactions of the two groups was class Ⅰ-Ⅱ. The incidence race of hand-foot syndrome of the observation group was higher than that of the control group(P<0.05). The nervous system， skin and subcutaneous tissue damage rate of the observation group was lower than that of the control group(P<0.05). There was no statistical difference in the incidence of the rest adverse reactions of the two groups(P>0.05).Conclusion： The combination of anrotinib and chemotherapy in the treatment of advanced non-small cell lung cancer has a significant short-term effect， and the quality of life has been improved significantly without increassing adverse effects.

Key words: font-size:medium, ">Anrotinib； Chemotherapy； Advanced non-small cell lung cancer； Side effects